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Abstract
Bckground: A number of studies have investigated whether the activity levels of enzymes involved
in 5-fluorouracil (5-FU) metabolism are prognostic factors for survival in patients with colorectal
carcinoma. Most reports have examined thymidylate synthetase (TS) and dihydropyrimidine
dehydrogenase (DPD) in unresectable or metastatic cases, therefore it is unclear whether the
activity of these enzymes is of prognostic value in colorectal cancer patients treated with radical
resection and adjuvant chemotherapy with 5-FU.
Methods: This study examined fresh frozen specimens of colorectal carcinoma from 40 patients
who had undergone curative operation and were orally administered adjuvant tegafur/uracil (UFT)
chemotherapy. TS, DPD and orotate phosphoribosyl transferase (OPRT) activities were assayed in
cancer tissue and adjacent normal tissue and their association with clinicopathological variables was
investigated. In addition, the relationships between TS, DPD and OPRT activities and patient
survival were examined to determine whether any of these enzymes could be useful prognostic
factors.
Results: While there was no clear relationship between pathological findings and TS or DPD
activity, OPRT activity was significantly lower in tumors with lymph node metastasis than in tumors
lacking lymph node metastasis. Postoperative survival was significantly better in the groups with low
TS activity and/or high OPRT activity.
Conclusion: TS and OPRT activity levels in tumor tissue may be important prognostic factors for
survival in Dukes' B and C colorectal carcinoma with radical resection and adjuvant chemotherapy
with UFT.
Background
Advanced colorectal carcinoma remains a significant
health care problem in developed countries. Even with
complete radical resection, almost half of patients
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develop local or distant recurrence presumably attributa-
ble to disseminated micro metastases present at the time
of surgery. Administration of 5-fluorouracil (FU) signifi-
cantly improves survival in patients with Dukes' C tumors
and may also be beneficial in patients with Dukes' B
tumors[1]. Nevertheless, a number of patients treated
with adjuvant chemotherapy still experience tumor recur-
rence within 5 years. Identification of highly specific prog-
nostic factors would aid in predicting the efficacy of
anticancer agents before the initiation of such therapies.
Thymidylate synthetase (TS), dihydropyrimidine dehy-
drogenase (DPD) and orotate phosphoribosyl transferase
(OPRT) are key enzymes in the regulation of 5-FU metab-
olism. TS is the rate-limiting enzyme in de novo pyrimi-
dine biosynthesis, and is inhibited by the 5-FU metabolite
5-fluoro-2-deoxyuridylate (FdUMP), leading to inhibi-
tion of DNA synthesis. In clinical studies of various malig-
nancies a correlation was observed between high levels of
TS and 5-FU resistance[2,3]. DPD is the initial enzyme in
the three-step metabolic pathway leading to the catabo-
lism of the pyrimidine bases uracil and thymidine; 70–
80% of administered 5-FU is degraded in vivo by DPD to
fluorinated β-alanine. Several studies have demonstrated
an association between high DPD levels and 5-FU resist-
ance. In advanced cases of unresectable colorectal carci-
noma, only those with low TS mRNA levels and low DPD
levels were found to respond to 5-FU treatment[4,5]. Sev-
eral in vitro studies suggested the major mechanism of 5-
FU resistance to be a marked decrease in 5-FU phosphor-
ylation by enzymes such as OPRT, which changes 5-FU to
FUMP in the presence of 5-phosphoribosyl-1-pyrophos-
phate. At present, it is still unclear whether OPRT is a key
activator of 5-FU and an accurate prognosticator of its
anti-tumor effects in a clinical setting. Several studies have
demonstrated that the activities of 5-FU metabolizing
enzymes such as TS, DPD and OPRT predict the efficacy of
chemotherapy with 5-FU for unresectable metastatic
colorectal cancer[6,7]; however, few reports have investi-
gated the relationship between the activity of these
enzymes and duration survival in patients with colorectal
carcinoma receiving radical operation combined with
adjuvant oral 5-FU chemotherapy[8,9].
Here, we analyze the ability of TS, DPD and OPRT activity
levels to predict the survival of colorectal carcinoma
patients receiving radical operation and adjuvant tegafur/
uracil, UFT®. It is not clear whether malignant processes
contribute to changes in the activities of these enzymes
within tumors; therefore, the present study also compared
enzyme activity in cancer tissue and surrounding normal
tissue.
Methods
Patients
Forty patients (23 males, 17 females; mean age of 68 ± 7
years) underwent their first colorectal resection at
National Kochi Hospital between April 2000 and April
2002. The experimental protocol was approved by the
Research Committee of National Kochi Hospital. All
patients were informed of the nature and risk of this
study, and written informed consent was obtained. The
patients were divided into two groups according to Dukes'
stage. Patients with Dukes' B corresponded with UICC
stage II A (T3pN0, n = 15) and UICC stage III A (T4pN0,
n = 7), and those with Dukes' C corresponded with UICC
IIIA (T3pN1, n = 11), UICC stage III B (T4pN1, n = 6) and
UICC stage III C (T4pN2, n = 1). Details concerning age,
gender, site and size of tumor and pathological findings
including histological classification, lymph node metasta-
sis and depth of tumor invasion are presented in Table 1.
All patients underwent radical operation with lymph
node dissection and received 300 mg/day oral tegafur/
uracil (UFT®; Taiho pharmaceutical Co., Japan), a fluoro-
pyrimidine inhibitor of dihydropyrimidine dehydroge-
nase, containing tegafur and uracil in a 1:4 molar ratio)
for a total of two years. No patient received radiation or
chemotherapy before surgery or enteral nutrition or other
chemotherapy during the study.
Methods
We investigated the relationship between clinical patho-
physiological characteristics and the activities of TS, DPD
and OPRT in 40 patients. We also studied whether the
activities of these enzymes were risk factors for recurrence.
Tissue was taken from the tumor and adjacent tumor-free
sites (> 5 cm from tumor) of the resected sample, and
immediately frozen in liquid nitrogen for preservation of
enzymatic activity. Samples were stored at -80°C until
use. TS, DPD and OPRT activities were examined in frozen
specimens as described by Fujii et al [8] as follows.
Table 1: Clinical and pathological parameters
Age (yrs) Male: Female Histological Type 
Well:mod
Tumor Location 
Colon: rectum
Nodal Status 
N0:N1:N2
Invasion Depth 
ss:se
Tumor Size(cm)
Dukes'B 67.9 ± 10.7 13:9 12:10 14:8 22:0:0 15:7 5.3 ± 1.3
Dukes'C 68.8 ± 5.6 10:8 10:8 12:6 0:17:1 11:7 5.5 ± 1.3
s.s.: histological tumor invasion of subserosa, s.e.: histological tumor invasion of serosa. Values represent mean ± SD.BMC Cancer 2008, 8:188 http://www.biomedcentral.com/1471-2407/8/188
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TS activity
TS enzyme activity was measured by tritium release assay.
Tissue was homogenized in 50 nM Tris HCl (pH 7.3) con-
taining 2 nM dithiothreitol. After ultracentrifugation
(105000 × g, 1 h, 4°C), the supernatant was collected and
incubated at 37°C with methylene tetrahydrofolic acid
and the substrate, [3H]-dUMP. Aliquots of the reaction
mixture were removed after 10, 20 and 30 min of incuba-
tion and the reaction was stopped immediately by adding
10% active carbon suspension containing 4% trichloro-
acetic acid. After centrifugation, 3H2O in the supernatant
was quantified with a liquid scintillation counter. The
reaction rate was obtained from the relationship between
reaction time and the amount of 3H2O formed. From this
reaction rate and the protein concentration (determined
separately), TS activity (pmol/min per mg protein) was
calculated.
DPD activity
DPD enzyme activity was measured in a sample of the
stored tissue by radioisotope-high performance liquid
chromatography (RI-HPLC). The tissue sample was
homogenized in 20 mM phosphate buffer (pH 8.0) con-
taining 1 mM ethylenediamine tetraacetic acid (EDTA)·2
K and 1 nM 2-mercaptoethanol. After ultracentrifugation
(105000 × g, 1 h, 4°C), the supernatant was collected and
incubated at 37°C in the presence of 6.25 mM nicotina-
mide adenine dinucleotide phosphate (NADPH) and 125
M [3H]-5-FU (25 Ci/ml). Aliquots of the reaction mixture
were removed after 10, 20, and 30 min of incubation, and
the reaction was stopped immediately by adding an equal
volume of 5% HClO4. The aliquots were diluted 1:2 with
a mobile phase consisting of 20 mM NaH2PO4 (pH 3.5),
and then centrifuged. The supernatant was analyzed using
the RI-HPLC conditions described below. The reaction
rate was obtained based on the relationship between reac-
tion time and the concentrations of 5-FU and its metabo-
lites 5-fluorodihydrouracil(5-FDHU), 2-fluoro-β-
ureidopropionate (FUPA), and α-fluoro-β-alanine
(FBAL). From this reaction rate and the protein concentra-
tion (determined separately), DPD activity (pmol/min
per mg protein) was calculated.
HPLC conditions
The column was a YMC-Pack Pro C18 (AS-301-3, 4.6 ×
100 min; YMC, Kyoto, Japan) kept at room temperature.
The guard column was a Guard-Pak Puresil C (Waters,
Milford, MA, USA). The mobile phase consisted of 20 mM
phosphate buffer (pH 3.5) and the flow rate was 0.5 ml/
min.
RI detection
The scintillation cocktail used was Pico Fluour40 (Perk-
inElmer Life Sciences, Boston, MA, USA). The scintillation
flow rate was 3.0 ml/min, and the injection volume was
40 μl.
OPRT activity
OPRT enzyme activity in samples of frozen tissue was
measured by the paper disk method. The tissue sample
was homogenized in 50 mM Tris-HCl (pH 7.5) contain-
ing 1.5 mM MgCl and 2 mM dithiothreitol. After ultracen-
Table 2: Patient characteristics and enzymes activities
Factor n TS activity Tumor: Normal colon DPDS activity Tumor: Normal colon OPRT activity Tumor: Normal colon
Mean Age: 40 10.8 ± 8.0 2.1 ± 1.2 28.1 ± 24.0 29.9 ± 14.6 0.50 ± 0.11 0.23 ± 0.07
Age:
young < 69 24 11.6 ± 8.7 2.6 ± 0.8 30.5 ± 28.9 28.6 ± 14.8 0.54 ± 0.10 0.20 ± 0.09
Old > 70 16 10.0 ± 8.1 1.6 ± 1.8 27.2 ± 20.7 30.7 ± 12.1 0.48 ± 0.14 0.25 ± 0.05
Gender:
male 23 12.1 ± 9.8 2.2 ± 1.4 25.8 ± 27.7 28.8 ± 15.8 0.54 ± 0.13 0.20 ± 0.09
Female 17 9.9 ± 9.5 2.0 ± 1.1 32.3 ± 21.3 30.6 ± 11.2 0.49 ± 0.12 0.24 ± 0.07
Histological type
Well 22 11.90 ± 5.6 2.3 ± 1.0 26.9 ± 21.8 31.8 ± 15.9 0.56 ± 0.12 0.20 ± 0.11
Moderately 18 10.0 ± 11.8 1.9 ± 1.5 30.5 ± 25.9 27.6 ± 11.8 0.45 ± 0.14 0.23 ± 0.05
Nodal status
N(-) 22 9.5 ± 10.2 2.7 ± 1.8 27.9 ± 27.8 32.0 ± 12.1 0.65 ± 0.11* 0.22 ± 0.08
N(+) 18 12.5 ± 6.9 1.5 ± 0.8 30.0 ± 22.8 26.5 ± 17.2 0.41 ± 0.13* 0.23 ± 0.07
Tumor depth
s.s. 26 10.0 ± 6.7 1.9 ± 0.9 27.5 ± 19.8 32.8 ± 11.5 0.54 ± 0.13 0.23 ± 0.08
s.e. 14 12.1 ± 9.8 2.3 ± 1.8 29.2 ± 29.7 26.1 ± 15.3 0.48 ± 0.11 0.23 ± 0.08
Tumor size
> 5.0 cm 27 9.5 ± 6.6 2.6 ± 1.0 27.7 ± 27.8 35.7 ± 19.9 0.54 ± 0.13 0.22 ± 0.07
< 4.9 cm 13 12.5 ± 9.5 1.7 ± 1.9 30.9 ± 20.8 23.9 ± 9.9 0.48 ± 0.12 0.23 ± 0.09
s.s.: histological tumor invasion of subserosa, s.e.: histological tumor invasion of serosa
*P < 0.05 (p mol/min/mg-protein)
Values represent mean ± SD.BMC Cancer 2008, 8:188 http://www.biomedcentral.com/1471-2407/8/188
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trifugation (105000 × g, 1 h, 4°C), the supernatant was
collected and incubated at 37°C with [3H]-5FU as the sub-
strate. Aliquots of the reaction mixture were removed after
5, 10, and 15 min of incubation, and the reaction was
stopped immediately by incubation in a 100°C water
bath. After centrifugation, the supernatant was placed on
an ion exchange filter paper made from diethylaminoe-
thyl (DEAE)-cellulose, and washed to remove unreacted
[3H]-5FU. The radioactivity of the [3H]-fluorouridine
monophosphate (FUMP) formed was quantified to deter-
mine the concentration of FUMP. The reaction rate was
obtained based on the relationship between the reaction
time and the concentration of the FUMP formed. From
this reaction rate and the protein concentration (deter-
mined separately), OPRT activity (pmol/min per mg pro-
tein) was calculated.
Statistical Analysis
Results are presented as means ± SD. The relationship
between disease severity (Dukes' B or C) and the activity
of each enzyme was evaluated with the Mann-Whitney
test. To evaluate the relationship between enzyme activity
and survival period, the subjects were divided into high-
activity and low-activity groups and differences were ana-
lyzed with the Pearson χ2 statistic. Linear regression anal-
ysis between two variables was done using a simple
regression method, the significance of which was quanti-
fied by analysis of variance (ANOVA). When disease-free
survival was used as an end point, an event included
recurrence of disease, death from cancer, and death from
non-cancer causes. Survival curves were constructed by the
Kaplan-Meier method. Multivariate analysis was per-
formed using the Cox's proportional hazards regression
model. A p value < 0.05 was considered significant.
Results
Relationship between enzyme activity and 
clinicopathological variables
Age, gender, and pathological findings such as histologi-
cal type, site and depth of tumor and tumor size except for
lymph node metastasis were similarly distributed between
the two groups (Table 1). TS, DPD and OPRT activities are
given in Table 2. In the tumor, mean values of TS, DPD
and OPRT activities were 10.8 ± 8.0 pmol/min/mg pro-
tein, 28.1 ± 24.0 pmol/min/mg protein and 0.50 ± 0.11
nmol/min/mg-protein, respectively. The ranges of TS,
DPD and OPRT activities in the tumor were 3.5–34.0
pmol/min/mg protein, 9.0–61.5 pmol/min/mg protein
and 0.34–0.78 nmol/min/mg protein, respectively. No
significant relationship was found between age or gender
and activity of these enzymes. TS and DPD activities
showed no clear relationship to any of the following path-
ological findings: histological type, lymph node metasta-
sis, depth of tumor and tumor size. However, OPRT
activity in the tumor was lower in Dukes' C than Dukes' B
(0.41 ± 0.13 vs. 0.65 ± 0.11 pmol/min/mg protein, P <
0.01), while TS and DPD activities exhibited no clear rela-
tionship with tumor staging.
Correlation between enzyme activity in colorectal tumor 
and adjacent normal tissue
The mean activities of TS, DPD and OPRT in non-tumor
sites were 2.1 ± 1.2 pmol/min/mg protein, 29.9 ± 14.6
pmol/min/mg protein and 0.23 ± 0.07 nmol/min/mg
protein, respectively. The mean TS and OPRT activities
were significantly higher (P < 0.01) in tumor tissue than
in adjacent normal tissue, but no significant difference
was found in DPD activity between tumor and adjacent
normal tissue. The correlation between TS activity in
tumor and adjacent normal tissue was high (r = 0.75, P <
Correlation between OPRT activity in tumor and adjacent  non-tumor tissue Figure 2
Correlation between OPRT activity in tumor and 
adjacent non-tumor tissue.
Correlation between TS activity in tumor and adjacent non- tumor tissue Figure 1
Correlation between TS activity in tumor and adja-
cent non-tumor tissue.BMC Cancer 2008, 8:188 http://www.biomedcentral.com/1471-2407/8/188
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0.001), while the correlation between OPRT activity in
tumor and adjacent normal tissue was weaker although
also statistically significant (r = 0.49, P < 0.01) (Fig. 1 and
2). No relationship existed between tumor/normal tissue
ratio of enzyme activity and age, gender, pathological
findings or Dukes' stage for any enzyme.
Correlation of enzymes activity and prognosis
By the Kaplan-Meier method, there were no significant
differences in disease-free survival between patients in
Dukes' B and C stages, with the 5-year disease-free survival
rates of 52% and 42% respectively. Disease-free survival
was significantly better in the low TS activity group (TS <
10.7) than the high TS activity group (TS > 10.7) (P <
0.05) (Fig. 3) and also in the high OPRT activity group
(OPRT > 0.51) than the low OPRT activity group (OPRT <
0.51) (P < 0.05), although no significant differences were
found between high and low DPD groups (Fig. 4). The
greatest increase in survival was observed for the group of
patients exhibiting both low TS activity and high OPRT
activity (78% in 5-year disease-free survival rate). Among
patients with Dukes' B or Dukes' C, disease-free survival
was significantly better in the high OPRT activity group
and the low TS group, respectively. Nine variables (TS,
DPD, OPRT, age, sex, tumor size, histological type, lym-
phatic metastasis and tumor depth) were analyzed using
the Cox's proportional hazards regression model to deter-
mine the factors affecting the survival of colorectal cancer
patients. Analyses showed TS activity (P = 0.05) and OPRT
activity (P = 0.03) to be significant variables that inde-
pendently predict postoperative survival (Table 3).
Discussion
Here, we report that neither TS nor DPD activities signifi-
cantly correlated with clinicopathological factors in
patients undergoing radical resection for colon cancer.
However, OPRT activity in tumors with lymph node
metastasis was significant lower than in tumors without
lymph node metastasis. This is similar to the observations
of Ochiai et al., who showed that metastasis to the lymph
nodes was associated with a significant reduction in the
tumor/normal tissue ratio of ORPT activity[9]. The fact
that the OPRT activity ratio for tumor tissue/normal tissue
significantly decreases as tumor stage increases in colorec-
tal carcinoma suggests that it may be possible to predict
lymphatic metastasis by determining OPRT activity in
tumor tissue prior to surgery. In contrast to our findings,
Ochiai et al. also reported that DPD activity levels were
high in poorly differentiated adenocarcinoma and muci-
nous carcinoma[9]. They also concluded that the expres-
sion of these enzymes may be associated with a poor
prognosis for patients with poorly differentiated adeno-
carcinoma and mucinous carcinoma who have been
treated with 5-FU.
Contradictory results have been reported in investigations
of the relationship between these enzymes activities and
clinicopathologic features. While we found no correlation
between TS activity and tumor size, depth, staging or other
pathological findings, Johnston et al. have reported that
TS activity in tumor tissue was significantly correlated
with tumor size, and that DPD activity in tumor tissue was
significantly higher in the patients with liver metastasis
than in those without metastasis[10]. Fujii et al.[8]
reported that TS and OPRT activities were high in carcino-
mas with high proliferative activity. However, similar to
Disease free survival for patients with high OPRT activity and  low OPRT activity Figure 4
Disease free survival for patients with high OPRT 
activity and low OPRT activity. The 5-year disease-free 
survival rates for high and low OPRT activity were 75% and 
28%, respectively. The difference in survival was statistically 
significant. (P < 0.05)
Disease-free survival for patients with high TS activity and  low TS activity Figure 3
Disease-free survival for patients with high TS activ-
ity and low TS activity. The 5-year disease-free survival 
rates for high and low TS activity were 34% and 73%, respec-
tively. The difference in survival was statistically significant. (P 
< 0.05)BMC Cancer 2008, 8:188 http://www.biomedcentral.com/1471-2407/8/188
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our findings, they showed no significant differences in
DPD activity with respect to clinicopathological variables.
The disparate conclusions reached regarding role of TS,
DPD and OPRT in colorectal tumors may be explained by
the different methodologies. The optimal method of
assessing TS, DPD and OPRT expression is unclear, but
current methods include immunohistochemistry (IHC),
reverse transcriptase polymerase chain reaction (RT-PCR)
and enzyme activity assay. The most common technique
used for survival analysis is IHC, which qualitatively
determines protein levels based on intensity of immunos-
taining. This method is difficult to standardize and cannot
provide a measure of enzyme activity. RT-PCR allows for
measuring marker expression in a highly sensitive manner
but requires fresh samples and it too cannot provide a
measure enzyme levels or activity. We chose to assay
enzyme activity because this method not only provides an
estimate of the absolute intracellular content, but also
allows provides a measure enzyme functionality,
although a disadvantage of this method is potential loss
of enzyme activity due to protein instability.
In the few reports comparing the expression of enzymes
involved 5-FU metabolism between tumor and normal
tissue, expression of the initial 5-FU-anabolizing enzymes
(OPRT, UP, TP, etc.) was elevated in human cancers as
compared with normal tissues[9,11,12]. Our study simi-
larly demonstrated higher TS and OPRT activities in
tumors than adjacent normal mucosa although we did
not note any significant difference in DPD activity
between the two. These findings indicate that 5-FU metab-
olism is increased in tumor tissue and is regulated by both
TS and OPRT[13]. Similar to our findings, Ichikawa[14]
and Fujii[8] have also reported a correlation between low
OPRT expression and worse prognoses or decreased
responses to chemotherapy. The increased expression of
these enzymes may promote proliferation of cancerous
cells via increased pyrimidine nucleotide biosynthesis. In
particular, biosynthesis of nucleic acid via increased sal-
vage synthesis is thought to be closely connected to tumor
growth. Using combined OPRT and TS quantitation, we
are able to identify a subgroup of Dukes' B or C patients
with a high recurrence rate and low disease-specific sur-
vival.
Our data also demonstrated that there was a significant
correlation between the activities of TS and OPRT in
tumor and disease-free survival (DFS) in patients receiv-
ing radical operation for colorectal carcinoma with adju-
vant chemotherapy with UFT. An inverse correlation was
observed between TS and DFS activities, while a positive
relationship was seen between OPRT and DFS activities,
as reported elsewhere [13-15]. Furthermore, we also
found that patients with low TS activity and high OPRT
activity survived longer, consistent with studies that have
reported TS activity to be a good parameter by which to
predict postoperative survival and to evaluate the effec-
tiveness of 5-FU[16,17]. In a study by Edler et al., patients
with low expression of TS in the tumor were found to have
increased DFS compared to those with high TS activ-
ity[18]. Several groups have investigated the predictive
value of DPD as an indication of sensitivity to 5
FU[19,20], suggesting that low levels of intratumoral
DPD expression are associated with 5-FU responsiveness.
However, our findings and the findings of Fujii et al.
found no clear relationship between DPD activity and 5-
FU sensitivity.[8] This discrepancy could be explained
either by the methodological differences or the broad
range in systemic DPD activity. Taking into account these
considerations, the role of DPD an indicator of as tumor
responsiveness for patients with DPD activity within the
normal range awaits further clinical investigation in a pro-
spective fashion before definitive conclusions.
Conclusion
The activity levels of TS and OPRT in tumor tissue may be
important prognostic factors for survival in Dukes' B and
C colorectal cancers with radical operation and adjuvant
chemotherapy with UFT. However, these conclusions are
drawn from a limited retrospective study. Further prospec-
tive research that enlists patients with or without adjuvant
chemotherapy will be required to establish the reliability
of these parameters for clinical prediction of 5-FU sensi-
tivity.
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